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http://dx.doi.org/10.1016/j.ajpath.2012.09.002This Month in AJPBiomarkers Found for Human Metaplasia
and Gastric Cancer
Early diagnosis and curative resection are associated
with increased survival in gastric cancer patients. Yet, a
majority of gastric cancers are still diagnosed at later
stages. Sousa et al (Am J Pathol 2012, 181:15601572)
uncovered novel biomarkers LTF and DNMT1 for spas-
molytic polypeptide-expressing metaplasia and intestinal
metaplasia, respectively, by generating proteome pro-
files using formalin-fixed, paraffin-embedded samples of
interstitial-type gastric cancer, metaplasia, and normal
mucosa by combining peptide isoelectric focusing
and liquid chromatography-mass spectrometry/mass-
spectrometry analysis. The authors further established
that the loss of LTF or DMBT1 expression in gastric
tumors correlates with a poor prognosis.
Large Oncosomes and Aggressiveness in
Prostate Cancer
Oncosomes are tumor-derived microvesicles that trans-
mit signaling complexes between cell and tissue com-
partments. Di Vizio et al (Am J Pathol 2012, 181:
15731584) demonstrated that such oncosomes contain
metalloproteinases, RNA, caveolin-1, and the GTPase
ADP-ribosylation factor 6 and are biologically active to-
ward tumor cells, endothelial cells, and fibroblasts. Flow
cytometry-based methods can selectively sort and ana-
lyze large oncosomes in mouse prostate cancer models
and human tumor tissues, demonstrating a correlation
with tumor progression in mice. Aside from establishing
techniques for the visualization, isolation, quantification,
and characterization of large tumor vesicles in tissues
and in the circulation, these findings suggest a mecha-
nism of conditioning tumor microenvironment and distant
site by migrating tumor cells, thereby potentiating ad-
vanced disease.
Necrostatin-1 Therapy for Retinal Detachment
Necroptosis, or programmed necrosis, is important in
embryonic development and pathophysiology as well as
neuronal cell death. Dong et al (Am J Pathol 2012, 181:
16341641) investigated the role of the necroptosis in-
hibitor necrostatin-1 on photoreceptor survival and func-
tional experimental retinal detachment in rats. By
introducing necrostatin-1 into the subretinal space at the
time of retinal detachment and 6 hours later, they ob-
served that necrostatin-1 directly protected neurons byspecifically inhibiting necroptotic cell death, inhibited re-
ceptor interacting protein kinase phosphorylation induc-
tion after retinal detachment, attenuated retinal degener-
ation, preserved retinal thickness, rescued neurons in the
outer retinal layers, and reduced functional impairment
after retinal detachment. There is therefore a promising
therapeutic role for necrostatin-1 in protecting photore-
ceptors from necroptosis and improving functional
outcome.
TIMP-3 Predicts Survival and Relapse in
Non–Small Cell Lung Cancer
Tissue inhibitor of metalloproteinase-3 (TIMP-3) is essential
for limiting inflammation. Wu et al (Am J Pathol 2012, 181:
17961806) hypothesized that TIMP-3 loss would induce
chronic inflammation, promoting tumor malignancy in hu-
man papillomavirus (HPV)-infected non–small cell lung can-
cer. TIMP-3 loss was more frequent in HPV 16/18-positive
tumors than in E6-negative tumors. Promoter hypermethyl-
ation resulted in decreased TIMP-3 expression, leading to
cell invasion and anchorage-independent growth due to
increased IL-6 production in otherwise E6-negative TL4 and
CL-10 lung cancer cells expressing E6. Patients with low-
TIMP-3/high-IL-6 tumors had shorter overall survival and
relapse-free survival periods than patients with high-TIMP-
3/low-IL-6 tumors. TIMP-3 may serve as a prognostic
marker for tumor recurrence in patients after surgical resec-
tion, and its loss may promote tumor malignancy, subse-
quent relapse, and poor survival in patients with HPV-
infected non–small cell lung cancer.
miR-200c Inhibits Melanoma Progression
The role of miRNAs in melanoma progression and drug
resistance has not been well studied. Liu et al (Am J Pathol
2012, 181:18231835) analyzed the role of miR-200c in
melanoma progression and demonstrated that miR-200c is
down-regulated in melanomas compared with melanocytic
nevi. miR-200c overexpresion in melanoma cells resulted in
decreased cell proliferation, migratory capacity, and drug
resistance that could be rescued by Bmi-1 overexpression;
down-regulation of BMI-1, ABCG2, ABCG5, andMDR1 with
a concomitant increase in E-cadherin levels and in vivo
inhibition of melanoma xenograft growth and metastasis
with decreased BMI-1 expression and E-cadherin levels in
tumors were also observed. Thus, miR-200c represents a
critical target for increasing melanoma sensitivity to clinical
therapies.
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